ZA200401302B - Combinations comprising cox-2 inhibitors and aspirin. - Google Patents

Combinations comprising cox-2 inhibitors and aspirin.

Info

Publication number: ZA200401302B
Authority: ZA; South Africa
Prior art keywords: aspirin; cox; inhibitors; combinations
Prior art date: 2001-10-11

Application number

ZA200401302A

Other languages

English (en)

Inventor

Alberto Gimona

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-11

Filing date

2004-02-18

Publication date

2005-01-04

2004-02-18 Application filed by Novartis Ag filed Critical Novartis Ag

2005-01-04 Publication of ZA200401302B publication Critical patent/ZA200401302B/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200401302A 2001-10-11 2004-02-18 Combinations comprising cox-2 inhibitors and aspirin. ZA200401302B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0124459.9A GB0124459D0 (en)	2001-10-11	2001-10-11	Organic compounds

Publications (1)

Publication Number	Publication Date
ZA200401302B true ZA200401302B (en)	2005-01-04

Family

ID=9923664

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200401302A ZA200401302B (en)	2001-10-11	2004-02-18	Combinations comprising cox-2 inhibitors and aspirin.

Country Status (19)

Country	Link
US (2)	US20040235802A1 (no)
EP (1)	EP1435968A1 (no)
JP (1)	JP2005505606A (no)
KR (1)	KR20040044891A (no)
CN (1)	CN1625405A (no)
AU (1)	AU2006249254A1 (no)
BR (1)	BR0213181A (no)
CA (1)	CA2458981A1 (no)
CO (1)	CO5570661A2 (no)
GB (1)	GB0124459D0 (no)
HU (1)	HUP0401854A2 (no)
IL (1)	IL160620A0 (no)
MX (1)	MXPA04003365A (no)
NO (1)	NO20041432L (no)
NZ (1)	NZ532158A (no)
PL (1)	PL369005A1 (no)
RU (1)	RU2004114560A (no)
WO (1)	WO2003033001A1 (no)
ZA (1)	ZA200401302B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040122011A1 (en) *	1998-12-23	2004-06-24	Pharmacia Corporation	Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7338971B2 (en) *	2001-08-30	2008-03-04	El-Naggar Mawaheb M	Treatment of inflammatory, cancer, and thrombosis disorders
EP1492511B3 (fr)	2002-04-09	2012-05-02	Flamel Technologies	Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
CA2487414A1 (en)	2002-06-11	2003-12-18	Nitromed, Inc.	Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1711454A4 (en) *	2004-01-27	2007-04-04	Merck Frosst Company	COMBINATION THERAPY FOR TREATING DISEASES OR CONDITIONS INDUCED BY CYCLOOXYGENASE-2 IN PATIENTS WITH RISK OF THROMBOTIC CARDIOVASCULAR EVENTS
EP1888045B1 (en) *	2005-05-24	2010-09-08	Flamel Technologies	Oral pharmaceutical composition for treating a cox-2 mediated condition
EP1919288A4 (en) *	2005-07-18	2009-12-16	Horizon Therapeutics Inc	FAMOTIDINE- AND IBUPROGEN-BASED MEDICAMENTS AND THEIR ADMINISTRATION
US20080021078A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Unit dose form for administration of ibuprofen
US8067451B2 (en)	2006-07-18	2011-11-29	Horizon Pharma Usa, Inc.	Methods and medicaments for administration of ibuprofen
US8067033B2 (en)	2007-11-30	2011-11-29	Horizon Pharma Usa, Inc.	Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) *	2006-08-31	2010-11-25	Horizon Therapeutics, Inc.	NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US9757529B2 (en) *	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US11696894B2 (en) *	2013-12-17	2023-07-11	Celsprin Llc	Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor
CN104173359B (zh) *	2014-09-05	2017-05-03	罗国安	一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2018167447A1 (en) *	2017-03-14	2018-09-20	University Of Sheffield	Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US10272107B2 (en) *	2017-09-05	2019-04-30	Kenneth O. Russell	Method for treating inflammatory brain disorders and traumatic brain injury
US10586872B2 (en) *	2018-07-03	2020-03-10	International Business Machines Corporation	Formation of wrap-around-contact to reduce contact resistivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4743596A (en) *	1987-06-16	1988-05-10	Lapin Alfred R	Anti-arthritic preparation
CO4960662A1 (es) *	1997-08-28	2000-09-25	Novartis Ag	Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6136804A (en) *	1998-03-13	2000-10-24	Merck & Co., Inc.	Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
PL351069A1 (en) *	1999-12-08	2003-03-10	Pharmacia Corp	Valdecoxib compositions
GB0002336D0 (en) *	2000-02-01	2000-03-22	Glaxo Group Ltd	Medicaments
AU2001285334A1 (en) *	2000-08-29	2002-03-13	Peter Van Patten	Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid

2001
- 2001-10-11 GB GBGB0124459.9A patent/GB0124459D0/en not_active Ceased
2002
- 2002-10-10 PL PL02369005A patent/PL369005A1/xx not_active Application Discontinuation
- 2002-10-10 JP JP2003535804A patent/JP2005505606A/ja active Pending
- 2002-10-10 MX MXPA04003365A patent/MXPA04003365A/es unknown
- 2002-10-10 HU HU0401854A patent/HUP0401854A2/hu unknown
- 2002-10-10 CA CA002458981A patent/CA2458981A1/en not_active Abandoned
- 2002-10-10 NZ NZ532158A patent/NZ532158A/en unknown
- 2002-10-10 BR BR0213181-1A patent/BR0213181A/pt not_active IP Right Cessation
- 2002-10-10 EP EP02779476A patent/EP1435968A1/en not_active Withdrawn
- 2002-10-10 US US10/487,759 patent/US20040235802A1/en not_active Abandoned
- 2002-10-10 WO PCT/EP2002/011380 patent/WO2003033001A1/en not_active Ceased
- 2002-10-10 KR KR10-2004-7003586A patent/KR20040044891A/ko not_active Ceased
- 2002-10-10 CN CNA028200853A patent/CN1625405A/zh active Pending
- 2002-10-10 IL IL16062002A patent/IL160620A0/xx unknown
- 2002-10-10 RU RU2004114560/15A patent/RU2004114560A/ru not_active Application Discontinuation
2004
- 2004-02-18 ZA ZA200401302A patent/ZA200401302B/xx unknown
- 2004-04-05 NO NO20041432A patent/NO20041432L/no not_active Application Discontinuation
- 2004-04-15 CO CO04034535A patent/CO5570661A2/es not_active Application Discontinuation
2006
- 2006-12-08 AU AU2006249254A patent/AU2006249254A1/en not_active Abandoned
2007
- 2007-08-07 US US11/834,748 patent/US20080027032A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20040044891A (ko)	2004-05-31
CN1625405A (zh)	2005-06-08
AU2006249254A1 (en)	2007-01-04
CO5570661A2 (es)	2005-10-31
HUP0401854A2 (hu)	2004-12-28
NO20041432L (no)	2004-06-28
IL160620A0 (en)	2004-07-25
GB0124459D0 (en)	2001-12-05
CA2458981A1 (en)	2003-04-24
RU2004114560A (ru)	2005-05-20
NZ532158A (en)	2006-04-28
BR0213181A (pt)	2004-08-31
WO2003033001A1 (en)	2003-04-24
JP2005505606A (ja)	2005-02-24
US20080027032A1 (en)	2008-01-31
EP1435968A1 (en)	2004-07-14
US20040235802A1 (en)	2004-11-25
MXPA04003365A (es)	2004-07-23
NO20041432D0 (no)	2004-04-05
PL369005A1 (en)	2005-04-18

Publication	Publication Date	Title
MXPA03005298A (es)	2003-10-06	Inhibidores de girasa y usos de los mismos.
MXPA03001832A (es)	2003-06-04	Derivados de hidroxamato utiles como inhibidores de desacetilasa.
ZA200204390B (en)	2003-08-27	Caspase inhibitors and uses thereof.
MXPA03008191A (es)	2004-01-29	Inhibidores de metaloproteinasa.
ZA200401302B (en)	2005-01-04	Combinations comprising cox-2 inhibitors and aspirin.
MXPA03008180A (es)	2003-12-12	Inhibidores de metaloproteinasa.
AP2005003251A0 (en)	2005-03-31	New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors.
MXPA03007310A (es)	2003-12-04	Derivados de ftalazinona piperidino como inhibidores pde4.
MXPA03008183A (es)	2003-12-12	Inhibidores de metaloproteinasa.
GB0129437D0 (en)	2002-01-30	Server and units
AU4217201A (en)	2001-10-03	Tri-aryl-substituted-ethane pde4 inhibitors
GB0114014D0 (en)	2001-08-01	Compostion and use
GB2376073B (en)	2004-10-06	Fluid-gauging systems and methods
IL172752A0 (en)	2006-04-10	Cox-2 and faah inhibitors
GB0229834D0 (en)	2003-01-29	Target and method
MXPA03007596A (es)	2003-12-11	Lacas de poliuretano de 1c de secado al horno y su uso.
GB0109278D0 (en)	2001-05-30	Enzyme inhibitors
GB0130624D0 (en)	2002-02-06	Centre finding ruler-CENTERULE
ZA200200611B (en)	2003-02-24	Caspase inhibitors and uses thereof.
AU2002328342A1 (en)	2003-03-03	Kinase inhibitors and the use thereof
ZA200204418B (en)	2004-01-22	Handling mechanism and method.
ZA200003398B (en)	2002-03-27	Inhibitors.
ZA200003399B (en)	2002-03-27	Inhibitors.
GB0108872D0 (en)	2001-05-30	Hedgehog and notch
HK1063733A (en)	2005-01-14	Caspase inhibitors and uses thereof